Product Reports Resources Pricing Login Book a demo

GeneDx Inc

Biotech & Life Sciences · Gaithersburg, United States · Founded 2000 · IPO 2020

Delivering personalized and actionable health insights that inform diagnosis, direct treatment, and improve drug discovery MoreLess

GeneDx is a pioneering company in the field of clinical genomics and rare disease diagnostics. The company specializes in genetic testing, which involves analyzing a patient's DNA to identify changes or mutations that could be linked to various health conditions. GeneDx serves a diverse range of clients, including patients, families, and healthcare providers, who rely on its expertise to gain deeper insights into genetic disorders.

Operating in the healthcare and biotechnology market, GeneDx has established itself as a leader by sequencing more than 300,000 clinical patient exomes. An exome is the part of the genome that contains genes, which are crucial for understanding genetic diseases. The company uses advanced techniques to collect DNA samples from cheek swabs, blood, or other specimens. These samples are then sequenced to detect genetic variations. The results are analyzed by a team of technical and clinical experts, and a detailed report is sent back to the healthcare provider.

GeneDx's business model revolves around providing rapid and accurate genetic testing services. They offer products like GenomeXpress and XomeDx Xpress, which deliver results in as little as seven days. This quick turnaround is vital for critical cases where timely diagnosis can significantly impact treatment outcomes, reduce hospital stays, and lower healthcare costs.

The company generates revenue by charging for its genetic testing services. Healthcare providers, hospitals, and clinics pay for these tests to diagnose and manage genetic conditions in their patients. Additionally, GeneDx offers digital Patient Letters, which provide personalized genetic information to patients and their families, enhancing their understanding of the test results.

In summary, GeneDx is at the forefront of clinical genomics, offering rapid and reliable genetic testing services that cater to patients, families, and healthcare providers. Their innovative approach and deep clinical expertise make them a key player in the personalized medicine landscape.

Keywords: Clinical Genomics, Genetic Testing, Rare Diseases, DNA Sequencing, Healthcare Providers, Rapid Diagnosis, Personalized Medicine, Exome Sequencing, Genetic Variations, Patient Letters.

Valuation $2.12B
Revenue $428M
EBITDA $13M
Total funding $500M–1B

Company overview

GeneDx Inc company information

The essential company record, classifications and operating signals in one place.

Status
Acquired
Founded
2000
Headquarters
Gaithersburg, United States
Employees
1,261
Open positions
29
Dealroom signal
94.9
Investment activity
1 companies · latest May 2025
Capital deployed
Preferred round
ACQUISITION
client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorSpinoutsectorBecame $1B as SubsidiarysectorBiotech and PharmasectorBecame Thoroughbred as SubsidiarysectorDT and LSsectorscience-based

Valuation & funding

GeneDx Inc funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITYOther financing May 2026 $43M Prosight Management
DEBTDebt Mar 2026 $100M Undisclosed
GROWTH EQUITY VCOther financing Nov 2025 $100M Undisclosed
DEBTDebt Oct 2023 $75M Perceptive Advisors
ACQUISITIONOther financing Jan 2022 $623M $623M Sema4
SPAC PRIVATE PLACEMENTOther financing Jul 2021 Perceptive Advisors
SPAC PRIVATE PLACEMENTOther financing Jul 2021 Perceptive Advisors
IPOOther financing Nov 2020 Undisclosed
SPINOUTOther financing Jan 2000 National Institutes of Health
Showing 9 recorded eventsUnlock the complete deal history →

Financials

Revenue, earnings and profit over time

Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.

YearRevenueGrowthEBITDAMargin
2026 $428M 0% $13M 3.1%
2025 $428M +40% $13M 3.1%
2024 $305M +50.8% $12M 4%
2023 $203M -13.7% −$127M -62.8%
2022 $235M +10.6% −$396M -168.6%
2021 $212M +18.3% −$424M -200%
2020 $179M −$227M -126.7%
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

GeneDx Inc website traffic

Latest recorded traffic for GeneDx Inc is 79K monthly website visits, up 23.4% over the last three months. GeneDx Inc's team grew 51.2% over the past year.

Latest monthly visits79K 3-month web change+23.4% 1-year team growth+51.2%
Monthly website visits47 observations · Jan 2022–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

GeneDx Inc compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Capital deployed

GeneDx Inc investments and acquisitions

Recent portfolio relationships for companies that also act as investors or acquirers.

Talent graph

GeneDx Inc's talent

Book a demo to see the people
Team profiled 24 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

4 investors on GeneDx Inc's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series B+ 2 investors entered at this stage
Perceptive Advisors
Prosight Management
Other known 2 additional known investors
National Institutes of Health
Sema4

Global footprint

Where GeneDx Inc has talent and traffic

Workforce by country
12 countries with
team presence
🇺🇸 United States94.4%
🇨🇦 Canada3.1%
🇮🇸 Iceland1%
🇵🇭 Philippines0.3%
🇬🇧 United Kingdom0.3%
Top 5 of 12 shown

In the news

Latest news about GeneDx Inc

Recent press, funding announcements, and product moves mentioning GeneDx Inc — open to read from the original sources.

See all news

Market sentiment

What the market is saying about GeneDx Inc

An AI-synthesized read of the highest-engagement posts about GeneDx Inc on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GeneDx Inc’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.